

Bevacizumab

## PRELIMINARY SCORE

### CURATIVE



### NON-CURATIVE



## ADJUSTMENTS

### Quality of life



### Serious and disabling adverse effects



### Other adjustments



Bevacizumab

## FINAL SCORE

### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

### INFORMATION

Tumour type: Thoracic Malignancies  
 Therapeutic Indication: First-line, unresectable advanced, metastatic or recurrent NSCLC other than predominantly squamous cell histology  
 Experimental Arm: Bevacizumab + Paclitaxel + carboplatin  
 Control Arm: Paclitaxel + carboplatin

